Skip to main content
Premium Trial:

Request an Annual Quote

GnuBio Moves to Bigger Space as it Prepares to Launch Desktop Sequencing Platform

NEW YORK (GenomeWeb News) – Next-generation sequencing instrument firm GnuBio said on Wednesday it is moving to a new 11,000-square-foot space to facilitate its transition to commercialization mode.

The new space is in Cambridge, Mass., where the firm is currently located, and will have laboratory space, allowing the company to prepare for the commercial launch of its desktop DNA sequencing technology. In addition to a general laboratory and office space for new hires in product development, software development, and sales and marketing, the facility will have manufacturing and fabrication capabilities, GnuBio said.

"The additional space will allow us to bring all initial manufacturing capabilities, from the consumables to the instrumentation, in house," GnuBio President and CEO John Boyce said in a statement. "The new facility will also provide the necessary space for the first critical hires for our commercial team."

The firm's desktop sequencing platform is based on microfluidic and emulsion technology licensed from David Weitz at Harvard University. GnuBio plans to launch the system at a list price of $50,000, and is working with partners to develop customized and standard panels to run on the system.

At the start of this year, GnuBio and its early-access customer, the Montreal Heart Institute, announced a collaboration to develop a genetic panel for predicting the risk of sudden cardiac death that will run on GnuBio's system.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.